Pharmacodynamic testing and new validated HPLC method to assess the interchangeability between multi-source orlistat capsules
Received 5 April 2017
Accepted for publication 22 July 2017
Published 21 November 2017 Volume 2017:11 Pages 3291—3298
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Rammohan Devulapally
Peer reviewer comments 2
Editor who approved publication: Dr Anastasios Lymperopoulos
Abdel Naser Zaid,1 Nihal Zohud,1 Bushra E’layan,1 Tasneem Aburadi,1 Nidal Jaradat,1 Iyad Ali,2 Fatima Hussein,1 Mashhour Ghanem,3 Aiman Qaddomi,3 Yara Abu Zaaror4
1Department of Pharmacy, 2Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, 3Department of Regulatory, Pharmacare PLC, 4Department of Research and Development Pharmacare PLC, Ramallah, Palestine
Background: Orlistat is an irreversible inhibitor of the lipase enzyme that prevents trigylcerides from being digested, thereby inhibiting triglyceride hydrolysis and absorption. The resultant reduced calorie uptake enables a positive effect on weight control. Systemic absorption of the drug is, therefore, not necessary for its mode of action. An alternative in vitro study (pharmacodynamic) has been introduced for this drug, as in vivo bioavailability studies are irrelevant with regard to the achievement of the product’s intended purposes.
Objectives: To develop a new validated high-performance liquid chromatography (HPLC) method for the analysis of orlistat and to assess the potency and equivalence of three orlistat formulations using the pharmacodynamic method as a surrogate indicator of pharmaceutical interchangeability.
Methods: A new HPLC method was developed for the analysis and for the dissolution studies of orlistat in capsules. Pancreatic lipase activity was measured for three different capsule products: Orlislim®, Slimcare®, and Xenical®, G1, G2, and the brand, respectively. Porcine pancreatic lipase and p-nitrophenyl butyrate (PNPB) were placed in a pH 7.4 reaction buffer at 37°C, and substrate hydrolysis was monitored by measuring absorbance changes at 410 nm; this was repeated on six capsules of each product. The inhibition was expressed by the concentration of product, which inhibited 50% of the activity of pancreatic lipase (IC50).
Results: The new analytical method was suitable for orlistat analysis. Values of IC50 from regression lines and equations were 6.14, 8.43, and 7.80 µg/mL for Orlislim®, Xenical®, and Slimcare®, respectively.
Conclusion: Pharmacodynamic studies of lipase inhibition could be used to support in vitro dissolution, which demonstrates interchangeability between generic and branded orlistat capsules. Moreover, it could be suggested as an alternative tool to bioequivalence studies for orlistat oral products.
Keywords: Orlistat, therapeutic equivalence, validation, pancreatic lipase
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]